pterostilbene Report issue

Small molecule Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a stilbenoid chemically related to resveratrol. In plants, it serves a defensive phytoalexin role.   Wikipedia

Chemistry

  • SMILES: COc1cc(/C=C/c2ccc(O)cc2)cc(OC)c1
  • InChIKey: VLEUZFDZJKSGMX-ONEGZZNKSA-N
  • Mol. Mass: 256.3
  • ALogP: 3.58
  • ChEMBL Molecule:
    pterostilbene  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

3',5'-dimethoxy-4e-stilbenol | 3,5-dimethoxy-4'-hydroxy-trans-stilbene | 3',5'-dimethoxy-4trans-stilbenol | 3',5'-dimethoxy-resveratrol | 4-((e)-2-(3,5-dimethoxyphenyl)ethenyl)phenol | 4trans-(2-(3,5-dimethoxyphenyl)ethenyl)phenol | phenol, 4-((1e)-2-(3,5-dimethoxyphenyl)ethenyl)- | pterostilbene | pterostilbene, (e)- | trans-3,5-dimethoxy-4'-hydroxystilbene | trans-pterostilbene

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Acute Kidney Injury (Phase 2)

Blood Pressure (Phase 2/Phase 3)

Endometrial Hyperplasia (Phase 2)

Endometrial Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Hyperlipidemias (Phase 2/Phase 3)

Oxidative Stress (Phase 2/Phase 3)

Recovery of Function (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue